Catalyst Event
AbbVie Inc (ABBV) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
4/13/2026, 12:00:00 AM
On April 13, 2026, AbbVie entered into an exclusive license agreement with Haisco Pharmaceutical to develop and commercialize a portfolio of novel pain compounds.
Korean Translation
2026년 4월 13일, 애브비는 하이스코 제약과 새로운 통증 화합물 포트폴리오의 개발 및 상업화를 위한 독점 라이선스 계약을 체결함.
Related Recent Events
Caris Life Sciences Inc (CAI) · Earnings Release
Next quarterly earnings report scheduled.
6/3/2026, 12:00:00 AM
NVIDIA Corporation (NVDA) · Earnings Release
NVIDIA Q1 FY2027 earnings release and conference call scheduled. Low importance is estimated as a date announcement typically has >=1% price impact.
5/27/2026, 12:00:00 AM
Hims & Hers Health Inc (HIMS) · Earnings Release
First quarter 2026 earnings release and conference call, for which low impact is estimated as the event has not yet occurred, scheduled.
5/11/2026, 12:00:00 AM
Tempus AI Inc (TEM) · Earnings Release
Tempus AI is expected to release its Q1 2026 earnings on May 5, 2026. Analysts forecast an EPS of -$0.21 to -$0.30, with the market pricing in a potential post-earnings stock price move of over 15% scheduled.
5/5/2026, 12:00:00 AM
BioNTech SE (BNTX) · Earnings Release
Q1 2026 financial results and corporate update scheduled.
5/5/2026, 12:00:00 AM
Recursion Pharmaceauticals Inc (RXRX) · Earnings Release
Q1 2026 earnings release for May 4, 2026, with analysts forecasting EPS of approximately -$0.27 and revenue of $20.73 million; Medium importance reflects expected volatility, and the event is scheduled.
5/4/2026, 12:00:00 AM